Set For Price War In India, Roche Renames Brands, Drops Prices Of MabThera, Herceptin By More Than Half
This article was originally published in PharmAsia News
Executive Summary
Part of a wider market-access plan for emerging markets, the Swiss drug maker is charting a new course in India that will help it enter newer pockets and consolidate its position.